0.05Open0.05Pre Close0 Volume90 Open Interest2.50Strike Price0.00Turnover324.26%IV155.26%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1751Delta0.3636Gamma20.00Leverage Ratio-0.0052Theta0.0001Rho3.50Eff Leverage0.0006Vega
Kronos Bio Stock Discussion
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibitionmodulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
The compa...
4 MINUTES AGO, 8:55 AM EDT
VIA GLOBENEWSWIRE
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –
New PK/PD results demonstrate that istisociclib given at 80mg on a 4 days on/3 days off schedule resulted in sustained downregulati...
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
Kronos Bio (NASDAQ: KRON) presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, at the AACR Ovarian Cancer Research Symposium. The data supports the clinical evaluation of istisociclib in advanced ovarian cancer, particularly in platinum and PARP-inhibitor resistant cases.
Key findings include:
Istisocic...
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provi...
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
• $Cogent Biosciences (COGT.US)$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions (UNVR.US)$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts (MTN.US)$ +6% (In reaction to earnings/guidance)
• $BeiGene (BGNE.US)$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
No comment yet